{
    "Trade/Device Name(s)": [
        "INFINITI CYP2C19 Assay"
    ],
    "Submitter Information": "AutoGenomics, Inc.",
    "510(k) Number": "K101683",
    "Predicate Device Reference 510(k) Number(s)": [
        "K073014",
        "K043576"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NTI",
        "NSU"
    ],
    "Summary Letter Date": "October 6, 2010",
    "Summary Letter Received Date": "October 8, 2010",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR862.3360",
        "21CFR862.2570"
    ],
    "Regulation Name(s)": [
        "Drug Metabolizing Enzyme Genotyping System",
        "Instrumentation for Clinical Multiplex Test Systems"
    ],
    "Analyte Class(es)": [
        "genetic molecular",
        "tdm"
    ],
    "Analyte(s)": [
        "CYP2C19*2",
        "CYP2C19*3",
        "CYP2C19*17"
    ],
    "Specimen Type(s)": [
        "Whole Blood"
    ],
    "Specimen Container(s)": [
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "AutoGenomics INFINITI Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Film-based microarray",
        "Process automation",
        "Reagent management",
        "Software analysis",
        "PCR amplification",
        "Allele specific primer extension",
        "Tag/Capture probe hybridization",
        "Microarray scanning",
        "Signal detection"
    ],
    "Methodologies": [
        "Microarray-based DNA genotyping",
        "PCR",
        "Automated allele detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent Module",
        "Microarray",
        "Amplification Mix"
    ],
    "Document Summary": "FDA 510(k) summary for INFINITI CYP2C19 Assay, a qualitative microarray-based genotyping test for detecting CYP2C19*2, *3, *17 mutations from whole blood using the INFINITI Analyzer.",
    "Indications for Use Summary": "Aids clinicians in determining therapeutic strategy for drugs metabolized by CYP450 2C19 based on detection of *2, *3, and *17 mutations in genomic DNA from EDTA-anticoagulated whole blood; not indicated for predicting drug response or nonresponse.",
    "fda_folder": "Toxicology"
}